Join
Live feed
·
PRReleasevia Quantisnow
Evaxion A/S logo

Evaxion's AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial

ByQuantisnow·Wall Street's wire, on your screen.
EVAX· Evaxion A/S
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track EVAX (Evaxion A/S) and more on Quantisnow.